logo

For the Inventor, By the Inventor

Durham, NC, United States of America

Parion Sciences, Inc.


USPTO Granted Patents = 83

% Expired Patents = 57.8



Forward Citations = 2,257

Loading Chart...
Loading Chart...

20 inventors (with patents filed for the assignee):

goldMedal Michael Ross Johnson (83 out of 170 patents)

silverMedal Richard C Boucher (15 out of 52 patents)

bronzeMedal William Robert Thelin (13 out of 13 patents)

4.  Jianzhong Zhang (12 out of 343 patents)

5.  Bruce Francis Molino (11 out of 41 patents)

6.  Bruce Sargent (11 out of 12 patents)

7.  Andrew J Hirsh (4 out of 4 patents)

8.  Tomas Navratil (3 out of 11 patents)

9.  Brian Button (3 out of 3 patents)

10.  Ronald A Aungst, Jr (2 out of 8 patents)

11.  Anthony James Hickey (1 out of 23 patents)

12.  Samuel E Hopkins (1 out of 4 patents)

13.  James B Fink (1 out of 25 patents)

14.  Stuart Robert Abercrombie (1 out of 2 patents)

15.  Mark Jeffrey Edhouse (1 out of 5 patents)


Core Competencies:
Sodium Channel Blockers
Mucolytic Agents
Aerosol Delivery Systems
Dendrimers
Pyrazinoylguanidine
Stable Blockers
Inhaled Saline
Hydration Enhancement
Epithelial Sodium Channel
Beta Agonist Activity
Phenolic Guanidine
Methods of Treatment

83 patents:

1. 11578042 - 3,5-diamino-6-chloro-N-(N-(4-(4-(2-(hexyl(2,3,4,5,6-pentahydroxyhexyl)amino)ethoxy)phenyl)butyl)carbamimidoyl)pyrazine-2-carboxamide (2023-02-14),
2. 10968233 - Monothiol mucolytic agents (2021-04-06),
3. 10752597 - 3,5-diamino-6-chloro-N—(N-(4-(4-(2-(hexyl(2,3,4,5,6-pentahydroxyhexyl)amino)ethoxy)phenyl)butyl)carbamimidoyl)pyrazine-2-carboxamide (2020-08-25),
4. 10526292 - Dendrimer like amino amides possessing sodium channel blocker activity for the treatment of dry eye and other mucosal diseases (2020-01-07),
5. 10526283 - Prodrugs of dithiol mucolytic agents (2020-01-07),
6. 10335558 - Methods of treatment (2019-07-02),
7. 10246425 - 3,5-diamino-6-chloro-N-(N-(4-phenylbutyl)carbamimidoyl) pyrazine-2-carboxamide compounds (2019-04-02),
8. 10233158 - Arylalkyl- and aryloxyalkyl-substituted epithelial sodium channel blocking compounds (2019-03-19),
9. 10167266 - Sodium channel blockers (2019-01-01),
10. 10159672 - Chemically and metabolically stable dipeptide possessing potent sodium channel blocker activity (2018-12-25),
11. 10106551 - Monothiol mucolytic agents (2018-10-23),
12. 10071970 - Chloro-pyrazine carboxamide derivatives with epithelial sodium channel blocking activity (2018-09-11),
13. 9987443 - Inhaled hypertonic saline delivered by a heated nasal cannula (2018-06-05),
14. 9963427 - Dithiol mucolytic agents (2018-05-08),
15. 9957238 - Arylalkyl-and aryloxyalkyl-substituted epithelial sodium channel blocking compounds (2018-05-01),
Parion Sciences, Inc. is a biopharmaceutical company focused on discovering and developing therapeutics to treat diseases of the epithelial lining of the respiratory and gastrointestinal tracts. They aim to develop innovative treatments for cystic fibrosis, chronic obstructive pulmonary disease (COPD), and other related conditions. By harnessing their expertise in epithelial biology, Parion Sciences aims to improve patients' quality of life through the development of novel drugs.
This text is generated by artificial intelligence and may not be accurate.

logo

Company Badge

USPTO Data Jan 1 1976 - Sep 15 2026

Parion Sciences, Inc.
83 Patents

#14 in Durham, NC

#116 in North Carolina

#4,462 in US

#9,124 in the World

Durham, NC (US)
Durham, NC, United States of America

Parion Sciences, Inc.

Forward Citations = 2,257

20 inventors:

goldMedal Michael Ross Johnson (83 out of 170 patents)

silverMedal Richard C Boucher (15 out of 52 patents)

bronzeMedal William Robert Thelin (13 out of 13 patents)

4.  Jianzhong Zhang (12 out of 343 patents)

5.  Bruce Francis Molino (11 out of 41 patents)

Please report any incorrect information to [email protected]
Loading…